Results 11 to 20 of about 8,073 (209)

PDE5 Inhibitors in Non-Urological Conditions [PDF]

Current Pharmaceutical Design, 2009
Phosphodiesterase type-5 (PDE5) inhibitors are widely used as first-line therapy for erectile dysfunction (ED). Their efficacy and safety combined with an increasing understanding of cyclic guanosine monophosphate (cGMP)-regulated mechanisms, have triggered a number of attempts to determine their effects and potential benefits in non-urological ...
Vlachopoulos, C., Terentes-Printzios, D., Ioakeimidis, N., Rokkas, K., Stefanadis, C.   +4 more
openaire   +4 more sources

PDE5 Inhibitors As Potential Tools In The Treatment Of Cystic Fibrosis [PDF]

Frontiers in Pharmacology, 2012
Despite great advances in the understanding of the genetics and pathophysiology of cystic fibrosis (CF), there is still no cure for the disease. Using phosphodiesterase type 5 (PDE5) inhibitors, we and others have provided evidence of rescued F508del ...
Sabrina eNoel, Barbara eDhooghe, Teresinha eLeal   +2 more
doaj   +2 more sources

Investigation of PDE5/PDE6 and PDE5/PDE11 selective potent tadalafil-like PDE5 inhibitors using combination of molecular modeling approaches, molecular fingerprint-based virtual screening protocols and structure-based pharmacophore development [PDF]

Journal of Enzyme Inhibition and Medicinal Chemistry, 2017
The essential biological function of phosphodiesterase (PDE) type enzymes is to regulate the cytoplasmic levels of intracellular second messengers, 3′,5′-cyclic guanosine monophosphate (cGMP) and/or 3′,5′-cyclic adenosine monophosphate (cAMP).
Gülru Kayık, Nurcan Ş. Tüzün, Serdar Durdagi   +2 more
doaj   +2 more sources

Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis. [PDF]

PLoS ONE, 2015
Urinary colics from calculosis are frequent and intense forms of pain whose current pharmacological treatment remains unsatisfactory. New and more effective drugs are needed to control symptoms and improve stone expulsion.
Peter Sandner, Hanna Tinel, Giannapia Affaitati, Raffaele Costantini, Maria Adele Giamberardino   +4 more
doaj   +4 more sources

The efficacy of PDE5 inhibitors in diabetic patients. [PDF]

Andrology, 2023
AbstractBackgroundPhosphodiesterase 5 inhibitors (PDE5i), since their introduction in the late 1990s, have proven their efficacy in treating several conditions, predominantly pulmonary hypertension and erectile dysfunction where they remain the first‐line therapeutic option.
Swiecicka A.
europepmc   +3 more sources

Discovery of Indole-Based PDE5 Inhibitors: Synthesis and Pharmacological Evaluation. [PDF]

ACS Med Chem Lett
Phosphodiesterase 5 (PDE5) inhibitors have been suggested as new treatments for Alzheimer’s disease (AD) and other conditions such as cancer and cardiovascular diseases.
Park SY, Pham D, Shukla P, Edward J, John R, Li A, Hadjiargyrou M, Mori M, Zuccarello E, Arancio O, Fiorito J.   +10 more
europepmc   +2 more sources

The impact of PDE5 inhibitors on cardiovascular outcomes. [PDF]

Glob Cardiol Sci Pract
Erectile dysfunction and cardiovascular disease share common underlying mechanisms, with the former being an early marker of cardiovascular risk. Phosphodiesterase-5 inhibitors, widely used as first-line therapy for erectile dysfunction, also exhibit systemic vasodilatory properties with potential cardiovascular implications.
Ghantous I, Tlais M, Khatib AE, Ghantous G, Maroun G, Challita A, Ayek M, Barmo G, Sahyoun M, El Kari G.   +9 more
europepmc   +3 more sources

Analysis of Phosphodiesterase-5 (PDE5) Inhibitors in Modulating Inflammatory Markers in Humans: A Systematic Review and Meta-Analysis. [PDF]

Int J Mol Sci
Phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil, tadalafil, and vardenafil, are primarily prescribed for erectile dysfunction and pulmonary hypertension. Emerging evidence suggests they may also modulate inflammatory pathways and improve
Cianciarulo C, Nguyen TH, Zacharias A, Standen N, Tucci J, Irving H.   +5 more
europepmc   +2 more sources

PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery. [PDF]

Br J Pharmacol, 2018
The discovery of the nitric oxide/cGMP pathway was the basis for our understanding of many normal physiological functions and the pathophysiology of several diseases.
Andersson KE.
europepmc   +2 more sources

Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health [PDF]

, 2023
Background: In 1999, 1 year after the approval of the first oral phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), the first Princeton Consensus Conference was held to address the clinical management of men with ED
Miner, Martin, Lue, Tom, Parish, Sharon J, Ganz, Peter, Sadeghi-Nejad, Hossein, Goldstein, Irwin, Sadovsky, Richard, McVary, Kevin T, Rosen, Raymond C, Burnett, Arthur L, Mulhall, John P, Kloner, Robert A, Blaha, Michael J, Sharlip, Ira D, Kim, Noel N, Kohler, Tobias   +15 more
core   +1 more source